COVID-19

While the peak of the COVID-19 pandemic seems to have passed, the effects of post-COVID conditions on public health remain. A new study led by Weill Cornell Medicine and NewYork-Presbyterian investigators has found that the risk of long COVID and its symptoms present very differently across diverse populations and suggests that further investigation is needed to accurately define the disease and improve diagnosis and treatment. 

A team led by researchers at Weill Cornell Medicine, the University of Wisconsin-Madison; Scripps Research and the University of Chicago has identified an antibody that appears to block infection by all dominant variants of the virus that causes COVID-19, including omicron, the most recent.

The activity of a gene called CIART is a key factor in the establishment of the viral infection that causes COVID-19.

Financial disruption as a result of pandemic containment policies in the United States adversely influenced children’s mental health.

Black and Hispanic patients were more likely than white patients to develop a wide array of lasting symptoms and conditions after a COVID-19 diagnosis.

The post-COVID syndrome known as long COVID has four major subtypes defined by different clusters of symptoms.

Individuals who were already pregnant at the beginning of the COVID-19 pandemic had a 50 percent lower exposure to...

A new study by HSS Research Institute and Weill Cornell Medicine scientists identifies a mechanism by which SARS-CoV-2 induces the inflammatory response in COVID-19 patient lungs, so-called “cytokine storm”, that can lead to lasting tissue damage and poor patient outcomes.

A new preclinical study by Weill Cornell Medicine investigators found that certain bacteria in the gut may reduce susceptibility to SARS-CoV-2 infection, improve the immune response and prevent blood clots that can occur in severe COVID-19 illness.

A recent Pfizer or Moderna mRNA-vaccine booster provided good but temporary protection against infection by the SARS-CoV-2 omicron variant.

SARS-CoV-2 infections of women in late pregnancy frequently spread to their placentas and led to inflammation.

Adult vaccination rates and social determinants of health—or the social and economic conditions in which families live and work—have played an important role in children’s mental health during the pandemic, according to a new study led by Weill Cornell Medicine investigators.

The SARS-CoV-2 virus can infect specialized pacemaker cells that maintain the heart’s rhythmic beat, setting off a self-destruction process within the cells, according to a preclinical study co-led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and NYU Grossman School of Medicine.

Booster doses of mRNA vaccines provided strong protection against hospitalization and death from COVID-19 in Qatar, though breakthrough SARS-CoV-2 infections were greater for the omicron variant compared with the delta variant, according to a study by investigators at Weill Cornell Medicine—Qatar.

Are you a COVID-19 ‘long-hauler’? Are you worried that your lingering exhaustion or shortness of breath indicate damage to your heart?

Weill Cornell Medicine has been awarded a $9.8 million grant from the National Institutes of Health to lead a consortium of health care institutions that are analyzing nationwide health data in an effort to unravel the complexities of long COVID.

An FDA-approved drug that has been in clinical use for more than 70 years may protect against lung injury and the risk of blood clots in severe COVID-19 and other disorders that cause immune-mediated damage to the lungs.

COVID-19 may bring high risks of severe disease and death in many patients by disrupting key metabolic signals and thereby triggering hyperglycemia, according to a new study from researchers at Weill Cornell Medicine and NewYork-Presbyterian. 

In a Q&A, Dr. Roy Gulick breaks down the science underlying COVID-19 booster shots and answers some frequently asked questions about the vaccines.

A group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate elicited durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical research.